EMEA-001710-PIP04-17

Key facts

Active substance
Ozanimod
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0050/2019
PIP number
EMEA-001710-PIP04-17
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of Crohn's disease
Route(s) of administration
Oral use
Contact for public enquiries
Celgene Europe Limited

Tel.+41 327298500
E-mail: medinfo.emea@celgene.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating